EUVIMEDEUVIMED entdecken
Crossref

Dosing and route of administration of clindamycin given in combination with rifampicin

Sophie Magréault, Racym Berrah, Younes Kerroumi, Léo Mimram, Dominique Salmon, Tiphaine Goulenok, Andrea de la Selle, Agnès Lefort, Simon Marmor, Najoua Hel Helali, Valérie Zeller, Vincent Jullien

Clinical Microbiology and Infection · 2025

DOI: 10.1016/j.cmi.2025.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Sophie Magréault und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité and Université Sorbonne Paris Nord, Inserm UMR 1137, IAME, Paris, France; Unité Fonctionelle de Pharmacologie, GHU Paris Seine …. Hauptthemen laut MEDLINE: Rifampin, Clindamycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The aim of this study was to develop a pharmacokinetic (PK) interaction model of intravenous (i.v.) and oral clindamycin when combined with rifampicin, and to determine whether appropriate clindamycin concentrations could be achieved for different doses and administration routes (oral, intermittent and continuous infusion) of clindamycin. METHODS: Five hundred and eighteen plasma samples were prospectively obtained from 124 patients treated for bone and joint infections. Population pharmacokinetic analysis was performed using Monolix software. Monte Carlo simulations were run to determine the probability of achieving a minimal clindamycin plasma concentration equal to at least twice the MIC, or an unbound area under the curve/MIC ≥60. RESULTS: A linear one-compartment model with first-order absorption and elimination was developed. Concomitant administration of rifampicin increased clindamycin clearance by an average factor of 3, whereas the impact on clindamycin bioavailability was dose dependent, with decreases from 56 to 11 and 4% for rifampicin doses of 600 mg and 900 mg q12 h, respectively. When administered simultaneously with rifampicin, satisfactory clindamycin concentrations could not be obtained when given orally. i.v. administration of a daily 3600 mg dose would be convenient for more than 80% of the patients, but doses of at least 4800 mg/d would be needed for a MIC equal to the 0.25 mg/L European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoint for Staphylococcus aureus. Intermittent i.v. administration every 6 hours is preferable to q8h regimens for the Cmin/MIC criteria, but still performed poorly compared with continuous infusion. DISCUSSION: This model satisfyingly described the differential effect of rifampicin on the bioavailability and clearance of clindamycin. As previously described, this combination must not be taken orally. However, administration of clindamycin doses of at least 3600 mg/d by intermittent or, preferably, continuous infusion, can balance the impact of rifampicin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinClindamycinAnti-Bacterial AgentsHumansMaleMiddle AgedFemaleAdministration, OralAdultMicrobial Sensitivity TestsAgedProspective StudiesYoung AdultDrug Therapy, CombinationMonte Carlo MethodAged, 80 and overDrug InteractionsPlasmaAdministration, IntravenousAdolescentBiological Availability

Stichwörter der Autor:innen

Bone and joint infectionsClindamycinDrug interactionPharmacokineticsPopulationRifampicin

Substanzen

RifampinClindamycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Université Paris Cité and Université Sorbonne Paris Nord, Inserm UMR 1137, IAME, Paris, France; Unité Fonctionelle de Pharmacologie, GHU Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de Paris, Université Sorbonn…
  • Université Paris Cité and Université Sorbonne Paris Nord, Inserm UMR 1137, IAME, Paris, France.
  • Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France.
  • Service de Médecine Interne, Hôpital Cochin, APHP, Paris, France.
  • Département de Médecine Interne, Hôpital Bichat-Claude Bernard, GHU APHP Nord, Université de Paris, Paris, France.
  • Service de Médecine Interne, Hôpital Beaujon, Clichy, GHU APHP Nord, Université de Paris, Paris, France.

Zitieren

APA

Magréault, S., Berrah, R., Kerroumi, Y., Mimram, L., Salmon, D., Goulenok, T., de la Selle, A., Lefort, A., Marmor, S., Helali, N. H., Zeller, V., & Jullien, V. (2025). Dosing and route of administration of clindamycin given in combination with rifampicin. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.01.005

Vancouver

Magréault S, Berrah R, Kerroumi Y, Mimram L, Salmon D, Goulenok T, et al. Dosing and route of administration of clindamycin given in combination with rifampicin. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2025.01.005

BibTeX
@article{Magrault2025,
  author = {Magréault, Sophie and Berrah, Racym and Kerroumi, Younes and Mimram, Léo and Salmon, Dominique and Goulenok, Tiphaine and de la Selle, Andrea and Lefort, Agnès and Marmor, Simon and Helali, Najoua Hel and Zeller, Valérie and Jullien, Vincent},
  title = {Dosing and route of administration of clindamycin given in combination with rifampicin},
  journal = {Clinical Microbiology and Infection},
  year = {2025},
  doi = {10.1016/j.cmi.2025.01.005}
}
Kostenlos starten →